Dichloroacetate Dosing via GSTZ1 Haplotype Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering dichloroacetate (DCA) do not account for individual variations in metabolism, leading to variable pharmacokinetics and increased risk of adverse effects due to polymorphisms in the GSTz1/MAAI gene, which affects dosing and toxicity.
Innovation Solution
Determining a patient's GSTz1/MAAI haplotype to identify fast and slow metabolizers, adjusting dosing regimens accordingly, and using arrays and kits to predict metabolizer status to prevent adverse drug effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standard dosing regime of DCA is administered to all patients, then treatment simplicity is maintained, but adverse drug effects increase due to individual metabolic variations
Solution Approach 1:
The patent performs GSTZ1/MAAI haplotype determination before DCA administration to identify slow metabolizers in advance. This preliminary genetic testing allows the system to predict which patients are at risk of adverse effects and adjust dosing regimens beforehand, preventing toxicity while maintaining treatment simplicity through standardized testing protocols.
2Object-affected harmful factors
If dosing is adjusted based on GSTZ1/MAAI haplotype, then adverse drug effects are reduced, but testing complexity increases
Solution Approach 1:
The patent introduces a standardized haplotype determination assay as an intermediary between genetic testing and dosing decisions. This assay simplifies the complex genetic analysis by providing clear haplotype classifications (fast vs. slow metabolizers) that directly guide dosing recommendations, making the overall process more manageable while maintaining accuracy in identifying at-risk patients.
3Productivity
If uniform DCA dosing is used, then administrative overhead is minimized, but treatment efficacy varies due to metabolic differences
Solution Approach 1:
The patent changes the dosing parameter from a fixed uniform dose to a variable dose based on GSTZ1/MAAI haplotype status. By categorizing patients into fast and slow metabolizer groups, the system creates discrete dosing levels that can be easily implemented while significantly improving treatment efficacy and reducing adverse effects compared to uniform dosing.
Data Source
AI summary
Embodiments of the present disclosure provide for methods, assays, and kits for predicting dosing for subjects. In addition, embodiments of the present disclosure include methods, assays, and kits, of determining if a patient can effectively metabolize one or both of phenylalanine and tryrosine.